Statewide Optimization of Lung Cancer Screening Utilizing the QUILS™ System in Nevada and Mississippi: State-Based Initiative Component

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-100
SponsorTimothy Mullett

About this trial

This clinical trial studies whether a Quality Implementation of Lung Cancer Screening (QUILS™) System state-based initiative (SBI) intervention works to improve the statewide capacity for implementing and sustaining lung cancer screening in Mississippi (MS) and Nevada (NV). The QUILS™ Group is focused on fair and high-quality implementation of lung cancer screening among eligible individuals to reduce lung cancer-related death in underserved communities. Previous research had success with implementing interventions in Kentucky which has lead to significant increases in lung cancer screening rates and a rapid decline in late-stage lung cancer diagnoses within the state. The goal is to offer the opportunity to replicate this work in states which are eager to address suboptimal screening rates, high lung cancer-related death, and significant health equity concerns. The QUILS™ SBI intervention involves translating the success of the initial work in Kentucky to impact lung cancer screening implementation and lung cancer outcomes in MS and NV through close collaboration with state-based partners. The QUILS™ SBI intervention may be an effective way to improve the statewide capacity for implementing and sustaining lung cancer screening in MS and NV.

Eligibility criteria

Qualifiers

Member of a state-based lung cancer screening implementation team in Mississippi or Nevada.

Leadership member of the Mississippi state team or Nevada state team

Active member of the Mississippi Lung Cancer Roundtable (MSLCRT) or Nevada Lung Cancer Coalition (NLCC)

Willing to participate in study-related assessments an implementation activities

Disqualifiers

None

Trial design

Treatments tested in this trial

  • QUILS SBI Intervention

Treatment groups

200 Participants
are divided into 1 treatment group

Sponsors and collaborators

Timothy Mullett

Lead sponsor

University of Kentucky

Sponsor institution